Merck KGaA
5-year stock timeline
Merck KGaA (MRK.XETRA) — currently trading at 120.35 — has navigated a complex six-year arc from pandemic-era tailwinds through strategic repositioning and into a more mature, diversified growth profile.
2020–2021: Pandemic resilience and Life Science momentum
The group weathered the initial pandemic shock with a strong Q1 2020 and accelerated from there. Life Science drove outsized growth, prompting management to raise guidance repeatedly through fiscal 2021. Investors at the time treated Merck as both a pandemic beneficiary and a pure-play Life Science leader, with the stock reflecting that narrative.
2022–2023: Portfolio discipline and M&A
Merck shifted gears toward targeted portfolio work. Key 2022 acquisitions included Mecaro and Exelead. Sales growth remained solid despite headwinds in parts of Life Science and Electronics. The market was noisier—macro concerns and sector softness created volatility and several failed breakout attempts, even as deal announcements suggested underlying strategic intent.
2024–2025: Return to growth and major consolidation
The company signaled a return to profitable growth and executed a string of acquisitions: Unity-SC and Mirus Bio in 2024, followed by the ~$3.4 billion SpringWorks Therapeutics deal in 2025. Results and guidance emphasized resilience despite currency and geopolitical friction. The investor narrative matured into a story about diversified, resilient healthcare and industrial exposure rather than a pure Life Science play.
Technical picture
The stock has spent the last two years consolidating in a mid-triple-digit band, digesting integrations and macro effects. Price action reflects the market pricing in return-to-growth messaging while remaining cautious on execution and macro noise.
Key risks and downside factors
Merck KGaA operates across life-science tools, specialty materials, and pharmaceuticals in a landscape dominated by large integrated players. The company faces real pressure on consumables and bioprocessing platforms where scale matters, and on specialty materials where it does too. Patent cliffs, regulatory shifts, and supply-chain disruptions aren't theoretical concerns—they move the needle on both revenue and margins in ways worth watching.
- Margin pressure from larger life-science tools and CDMO competitors with greater scale and pricing power.
- Revenue volatility tied to patent expiries and clinical or regulatory setbacks in the pharmaceuticals holdings.
- Regulatory and reimbursement shifts in major markets—the kind that can stall approvals or squeeze therapy pricing—remain a persistent headwind worth tracking.
- Supply-chain disruptions, raw-material shortages, and specialty-materials constraints that drive up costs or limit production capacity in electronics and life-science segments
Competitive landscape
Merck KGaA operates across Life Science, Healthcare, and Electronics, where it contends with entrenched competitors—particularly large tools manufacturers and CDMOs that dominate bioprocessing and lab consumables. The Healthcare division faces near-term pressure from the U.S. loss of exclusivity for Mavenclad, while Life Science and Electronics are squeezed by pricing competition and scale advantages held by global suppliers and materials specialists. Patent and exclusivity cliffs loom as material risks, alongside regulatory and reimbursement headwinds. Foreign-exchange swings and supply-chain disruptions can meaningfully shift reported results in ways that aren't always predictable.
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Merck KGaA
Relative Performance vs Benchmarks
| Period | Merck KGaA | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +4.44% | +4.20% | +0.91% |
| 3M | -4.02% | -1.75% | -11.51% |
| 6M | +9.32% | +3.33% | -2.65% |
| 1Y | +4.75% | +2.92% | -20.43% |
| 3Y | -23.78% | -74.16% | -105.92% |
| 5Y | -11.46% | -70.01% | -100.79% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 20.7 | 2.5 | 1.8 | 12.5 |
| 1Y ago | 17.7 | 2.3 | 1.7 | 12.2 |
| 3Y ago | 22.3 | 3.2 | 2.8 | 16.9 |
| 5Y ago | 27.2 | 3.5 | 3.3 | 14.9 |
Frequently Asked Questions
Where is the Merck KGaA stock traded?
What does Merck KGaA do?
What are the key metrics for MRK.XETRA?
How has Merck KGaA's stock price performed?
How is MRK.XETRA valued?
Does MRK.XETRA pay dividends?
What are the key risks when investing in MRK.XETRA?
- Margin pressure from larger life-science tools and CDMO competitors with greater scale and pricing power.
- Revenue volatility tied to patent expiries and clinical or regulatory setbacks in the pharmaceuticals holdings.
- Regulatory and reimbursement shifts in major markets—the kind that can stall approvals or squeeze therapy pricing—remain a persistent headwind worth tracking.
- Supply-chain disruptions, raw-material shortages, and specialty-materials constraints that drive up costs or limit production capacity in electronics and life-science segments
Who are the main competitors of Merck KGaA?
When does Merck KGaA report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 2.20 EUR | 1.97% | 1.35% |
| 2025 | 2.20 EUR | 1.82% | |
| 2024 | 2.20 EUR | 1.45% | |
| 2023 | 2.20 EUR | 1.35% | |
| 2022 | 1.85 EUR | 1.05% | |
| 2021 | 1.40 EUR | 0.97% | |
| 2020 | 1.30 EUR | 1.23% | |
| 2020 | 1.30 EUR | 1.24% | |
| 2019 | 1.25 EUR | 1.31% | |
| 2018 | 1.25 EUR | 1.51% | |
| 2017 | 1.20 EUR | 1.11% | |
| 2016 | 1.05 EUR | 1.28% | |
| 2015 | 1.00 EUR | 0.95% | |
| 2014 | 0.95 EUR | 1.55% | |
| 2013 | 0.85 EUR | 1.46% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 21.10B | 21.16B | 20.99B | 22.23B | 19.69B |
| Operating income (EBIT) | 4.07B | 4.37B | 4.04B | 5.00B | 4.28B |
| Net income | 2.61B | 2.78B | 2.82B | 3.33B | 3.06B |
| Free cash flow | 2.35B | 2.40B | 1.76B | 2.45B | 3.19B |
| Total assets | 52.10B | 51.57B | 48.49B | 48.53B | 45.36B |
| Equity | 28.59B | 29.91B | 26.68B | 25.93B | 21.34B |
| Net debt | 9.23B | 8.12B | 7.96B | 9.00B | 9.26B |
PWP Leeway UG (haftungsbeschränkt)
